In a calculated strategy to streamline its common stock structure and meet compliance requirements, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a Boston-based, clinical-stage biopharmaceutical company, has announced its decision to implement a 1-for-20 reverse stock split. The move, approved by stockholders at the company’s recent annual meeting, is expected to enhance the company’s financial positioning and […]
